Evidence collected in a number of laboratories is consistent with the synthesis, breakdown and resynthesis of NAD+ via the series of reactions shown in Figure 1 . The de novo biosynthesis of NAD proceeds from tryptophan in some organisms and from the condensation of 3 carbon and 4 carbon moieties in others, but QA is a common intermediate in both pathways.
In mammals, Neurospora, aerobically grown yeast and Xanthomonas pruni tryptophan is the precursor of QA. In higher plants and many microorganisms, QA is formed from aspartate and glycerol (or closely related compounds) (1) , by a series of reactions which have not yet been elucidated.
The PRPP dependent conversion of QA to NaMN was first demonstrated in liver homogenates by Nishizuka and Hayaishi (2) . The responsible enzyme, quino linate phosphoribosyl transf erase, was purified at Oklahoma State University and the reaction shown to proceed in a single step (3, 4) . This work was immediately confirmed by the Kyoto Group (5).
The "salvage pathway" for NAD+ biosynthesis proceeds from NA or nicotin amide. The steps between NA and NAD+ were elucidated by Preiss and Handler (6) , and the pathway from nicotinamide in mammalian liver was completed by the discovery of hepatic nicotinamide deamidase in Greengard's laboratory (7) . A possible alternate route for the formation of NAD from nicotinamide via NMN was provided by the discovery by Dietrich et al. (8) of a low Km NMN pyrophos phorylase in liver and other mammalian tissues. However, the total activity of this enzyme in liver is much less than that of the analogous enzyme which acts on NA, and several other lines of evidence also suggest that in liver the main salvage pathway proceeds via NA (9) . Furthermore, the NMN pathway is absent from E . coli (10) . The cycle is completed by the cleavage of NAD+ to reform nicotin amide by NAD glycohydrolases which are almost ubiquitously distributed in nature. The recent discovery of the nuclear enzyme which polymerizes NAD+ with the release of nicotinamide (11) provides another, and perhaps more important, reaction which requires the recycling of nicotinamide through NAD+.
Let us first consider some possible regulatory effects in the de novo pathways of NAD+ biosynthesis.
Wagner (12) proposed that NAD+ may regulate its syn thesis from tryptophan in liver by feedback inhibition of tryptophan pyrrolase, the first enzyme on the tryptophan-NAD+ pathway. Cho-Chung and Pitot (13) support this suggestion but have found that NADPH is the most potent inhibitor among the pyridine nucleotides tested. We have obtained evidence that such a control mechanism operates in vivo by measuring evolution of 14CO2 from injected tryptophan-indole-2-14C as an index of tryptophan pyrrolase activity in rats in which hepatic NAD concentrations had been elevated by administration of nicotinamide. As shown in Figure 2 (14) , there is an inverse relationship between hepatic NAD+ concentration and excre tion of 14CO2. These data suggest that NAD+, or a closely related compound, acts as a feedback inhibitor of tryptophan pyrrolase in vivo.
Regulation of de novo NAD+ biosynthesis is also observed in organisms which do not use the tryptophan pathway for formation of QA. Growth in Bacillus subtilis or B. megatherium on media containing 10-5 M or higher concentrations of NA results in repression of quinolinate phosphoribosyl transf erase ( Table 2 ). The corepressor in this case is presumed to be NAD+ or a related compound formed from NA by NaMN pyrophosphorylase which is not repressed in these organisms.
Although it is repressed, quinolinate phosphoribosyl transf erase from B. subtilis is not inhibited by NAD+ or related compounds (15) . In contrast to the findings in Bacillus the quinolinate phosphoribosyl transf erase of E . coli is not repressed by growth of this organism on NA. (See Table 4 ) . However, repression of the enzyme system which synthesizes QA from aspartate is observed in E. coli (Table 3) . Cell-free extracts of E. coli 126, a mutant lacking Nicotinamide deamidase is another point on the salvage pathway at which regulation has been demonstrated.
Greengard et al. (22) showed that in hypophy sectomized rats injection of nicotinamide leads to a much larger and more pro longed rise in hepatic NAD levels than in normal rats ( Figure 5 ). This effect may be due, at least in part, to an increased hepatic nicotinamide deamidase activity brought about by the absence of an endogenous inhibitor of this enzyme in Rats (23) hypophysectomized rats. The inhibitor appears to act by increasing the Km for nicotinamide (23) (Figure 6 ), The endogenous inhibitor of nicotinamide deamidase present in normal liver but absent in hypophysectomized animals has been variously identified as an acidic lipid (24) and as thyroxine (25) . Kaplan (26) has emphasized the possible role of the degradation of NAD+ by NAD+ glycohydrolase in controlling NAD+ levels. Grunicke et al. (27) Greengard et al. (28) , as well as in our labora tory, suggest that such a control mechanism may be operating.
Considerably more N1-methylnicotinamide is excreted by normal rats than by hypophysectomized rats following injection of 500 mg/kg nicotinamide (Figure 7 ). This increase may be correlated with an increased activity of nicotinamide methyl transf erase (Table 5 ).
Eight hours after intraperitoneal injection of 500 mg/kg nicotinamide into normal rats, hepatic nicotinamide methyl transferase activity was elevated 60-100% above basal levels.
This increase was not observed in hypophysectomized rats, and a similar increase was produced by injection of hydrocortisone.
These findings sug gest a hormonal basis for the regulation of nicotinamide methyl transf erase activity. Dr. C. Streffe: I am very much interested in your work on tryptophan pyrrolase . In one of your slide, I saw the inhibition of tryptophan pyrrolase and that the concen tration of NAD (1 mg/g liver) was very low . This is a physiological concentration of NAD in the liver. I would like to know whether you did other experiments giving some evidence of the regulation of NAD synthesis by tryptophan pyrrolase. were done with the enzyme purified from the beef liver.
We have also two other enzymes; one is nicotinic acid ribonucleo tide pyrophosphorylase from yeast, and the other is nicotinamide ribonucleotide pyro phosphorylase from Lactobacillus fructo sus. The latter two enzymes also require ATP in addition to PP-ribose-P. With all these enzymes, ATP has been shown to be expended in a stoichiometric quantity in a low concentration of the substrate. We have no direct evidence at this moment that a single enzyme protein is involved in the re actions in the presence and absence of ATP. However, if we assume so, ATP must act as both allosteric effector in a narrow sense and indeed substrate at the same time. I think we are still very far from complete understanding of the whole picture of this situation and the reaction mechanism. Now, the question I am asking is whether or not ATP is broken in your system dependent upon the substrate utilized.
Dr. R. K. Gholson:
Yes, we confirmed with the yeast enzyme a beautiful stoichiometry. We have also observed with the mammalian enzyme that at low level of nicotinic acid ATP is definitely split but we did not get a very good stoichiometry.
